Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Medication adherence failure in schizophrenia: A forensic review of rates,reasons, treatments, and prospects
Autore:
Young, JL; Spitz, RT; Hillbrand, M; Daneri, G;
Indirizzi:
Connecticut Valley Hosp, Whiting Forens Div, Middletown, CT 06457 USA Connecticut Valley Hosp Middletown CT USA 06457 Middletown, CT 06457 USA Yale Univ, Sch Med, New Haven, CT 06520 USA Yale Univ New Haven CT USA 06520 e Univ, Sch Med, New Haven, CT 06520 USA Albert Einstein Coll Med, Bronx, NY 10467 USA Albert Einstein Coll Med Bronx NY USA 10467 Coll Med, Bronx, NY 10467 USA
Titolo Testata:
JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW
fascicolo: 3, volume: 27, anno: 1999,
pagine: 426 - 444
SICI:
1093-6793(1999)27:3<426:MAFISA>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
NEUROLEPTIC-INDUCED AKATHISIA; DRUG-INDUCED AKATHISIA; SERIOUSLY MENTALLY-ILL; DOUBLE-BLIND TRIAL; FLUPHENAZINE DECANOATE; FOLLOW-UP; EXPRESSED EMOTION; SUBSTANCE-ABUSE; ANTIPSYCHOTIC MEDICATION; CLINICAL CHARACTERISTICS;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Citazioni:
195
Recensione:
Indirizzi per estratti:
Indirizzo: Young, JL Box 70, Middletown, CT 06457 USA Box 70 Middletown CT USA 06457Box 70, Middletown, CT 06457 USA
Citazione:
J.L. Young et al., "Medication adherence failure in schizophrenia: A forensic review of rates,reasons, treatments, and prospects", J AM A PSYC, 27(3), 1999, pp. 426-444

Abstract

Forensic patients with schizophrenia who fail to adhere to prescribed antipsychotic medication risk recidivism, which continues to be a serious concern. it affects ail stages of trial proceedings and impacts on the treaters'liability. Although much remains unchanged since the authors reviewed the subject in 1986, significant advances have occurred. A patient's insight can be assessed with greater precision. Risks posed by past noncompliance, substance abuse, and a dysphoric response to medication are more clearly documented. Clinical and laboratory methods for assessing compliance have improved. Major advances in the effective amelioration of adverse effects can beapplied to promote adherence. New augmentation strategies enable adequate treatment at lower doses. The development of atypical antipsychotic agents makes compliance easier to achieve and maintain. Other advances apply to the containment of relapse when it does occur. This review organizes the literature documenting these trends for use in both treatment and consultation.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 18:44:07